Masimo Corporation Affirms FDA Warning Letter Over Pronto 7 Monitor

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The FDA sends a warning letter to Masimo, saying the company doesn't have procedures in place to adequately investigate and document device failure complaints for its Pronto 7 pulse oximeter. FDA warns Masimo on inadequate complaint reviews

Masimo (NSDQ:MASI) said it received a warning letter yesterday from the FDA over its procedures for reporting and investigating failure complaints for its Pronto 7 pulse oximeters.

The FDA inspected Masimo's Irvine, Calif., facility from August to October last year and issued a Form 483 detailing several complaint procedure violations, according to a regulatory filing.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC